159 related articles for article (PubMed ID: 36264603)
1. GPRASP1 is a candidate anti-oncogene and correlates with immune microenvironment and immunotherapeutic efficiency in head and neck cancer.
Zhang T; Liu G; Zhang J; Chen S; Deng Z; Xie M
J Oral Pathol Med; 2023 Mar; 52(3):232-244. PubMed ID: 36264603
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
4.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
6.
Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
[TBL] [Abstract][Full Text] [Related]
7. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
11.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
12. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
14. Identification of cuproptosis-related subtypes and characterization of the tumor microenvironment landscape in head and neck squamous cell carcinoma.
Huang J; Xu Z; Yuan Z; Cheng L; Zhou C; Shen Y
J Clin Lab Anal; 2022 Sep; 36(9):e24638. PubMed ID: 36082469
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
17. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
Front Immunol; 2022; 13():964118. PubMed ID: 36059470
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
19. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
Front Immunol; 2022; 13():834142. PubMed ID: 35242138
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]